Cedocef TZ
(Cefoperazone & Tazobactam 1.125gm Vial)
INDICATIONS
- Gynecological infections
- Urinary Tract infections
- Post-operative infections
DOSAGE AND ADMINISTRATION
- Usual adult dosage 2 to 4 g daily given in equally divided doses every 12 hours (in terms of Cefoperazone).
- Preferably administered by IV infusion but may also be given by deep IM injection.
- IV infusion should be given slowly over 15 to 30 minutes
Comparative in-vitro activity of Cefoperazone - Tazobactam and Cefoperazone - Sulbactam combinations against ESBL pathogens 8 in Respiratory and Urinary infections .
54 samples were collected from 9 hospitals in Mumbai
| 34 samples of urine | 20 samples of sputum | ||
|---|---|---|---|
| Pathogens | No of Isolated | Pathogens | No of Isolated |
| E. coli | 27 | 6 | 1 |
| K. pneumoniae | P. aeruginosa | S. pneumoniae | K. pneumoniae |
| Serratia marcescens | 5 | 1 | 14 |
Kirby Bauer disc diffusion method was used to evaluate the susceptibility of the isolated pathogens to Cefoperazone - Tazobactam and Cefoperazone - Sulbactam.
In sputum samples
- All the isolates of P. aeruginosa were susceptible to Cefoperazone-Tazobactam while one isolate was resistant to Cefoperazone-Sulbactam.
- S. pneumoniae and K. pneumoniae were sensitive to both the antibiotic formulations.
| Pathogens | Susceptibility Rates | |
|---|---|---|
| Cefoperazone-Tazobactam | Cefoperazone-Sulbactam | |
| E. coli | 96% | 89% |
| Klebsiella | 83% | 67% |
| Serratia marcescens | Highly susceptible | Intermediate resistant |
| K. pneumoniae | Highly susceptible | Resistant |
CONCLUSION :This study corroborate the efficacy of the B-lactamase inhibitor Tazobactam in improving the spectrum of activity and efficacy of Cefoperazone.